Streetwise Reports' Article Archives — Current Month (8)
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVIDô, its COVID-19 vaccine candidate.
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report.
Preclinical COVID-19 Vaccine Data 'Encouraging' (07/08/2020)
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report.
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications.
Analyst: G1 Minimizes the Carnage of Chemotherapy (07/01/2020)
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA.
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report.
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2.
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients.